Compare Coursera Inc (COUR) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Eli Lilly And Co — how do they compare? Coursera Inc trades at $5.28 (market cap $1.35B), while Eli Lilly And Co trades at $1,166.49 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 785.2× Coursera Inc's market cap, and Eli Lilly And Co pays a 0.58% dividend while Coursera Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Eli Lilly And Co for 93 Days on average.
| COUR | LLY | |
|---|---|---|
Market Cap | $1.35B | $1.06T |
Volume | 5,442,629 | 2,297,239 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $1.28K |
52-Week Low | $4.64 | $799.57 |
Typical Hold Time | 47 Days | 93 Days |
Enterprise Value | $606.18M | $1.11T |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.27, up 2.93% with a bearish technical signal despite recent earnings beats. Revenue growth is solid (2025: $758M, 2026: $885M projected) but profitability remains negative with a -15.39% net margin. Analyst consensus is bullish with a $7.40 price target (52.94% buy ratings), while institutional activity shows mixed positioning amid Project Helix AI platform developments.
The stock offers upside potential from AI-driven growth and margin improvements, but faces execution risks on profitability and integration costs. High RSI near 82 suggests overbought conditions, while persistent net losses and competitive pressures in edtech warrant caution for near-term volatility.
Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.
Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
